Higher Degree by Research Candidate
Adelaide Medical School
Faculty of Health and Medical Sciences
I was graduated from Ain Shams Medical School, Cairo, Egypt, with grade excellent with honour in 2003. I had one year as intern at Ain Shams University hospitals. In 2005, I started my residency training at the Clinical Oncology Department, Ain Shams University hospitals. I got my master degree in Clinical Oncology in 2008. I worked as Medical Oncology specialist for one year in Cairo, then I travelled to Dubai, UAE, where I worked as medical oncology specialist for 5 years at Dubai Hospital. In 2010 I got my Medical Oncology certification from the European Society of Medical Oncology (ESMO). In 2013, I got my Medical Oncology Speciality certification from the Royal College of Physician, UK. In 2015, I moved to Kingdom of Bahrain where I worked as Senior medical oncology specialist at Salmaniya Medical Complex, Manama. In 2016 I was awarded PhD scholarship from the University of Adelaide. I started my PhD in June 2016.
My PhD is about the effect of obesity and abnormal metabolic profile on prostate cancer incidence and aggressiveness. I am working on two large data sets from Australia and the United States to explore the link and causal effect of obesity and abnormal lipid profile on prostate cancer. I am part of the Lipid and Prostate cancer research group, based at SAHRMI , Adelaide, SA. My work is under the supervision of Prof. Lisa Butler, the team leader of the group.
Language Competency Arabic Can read, write, speak, understand spoken and peer review English Can read, write, speak, understand spoken and peer review French Can read
Date Institution name Country Title 1997 - 2003 Ain Shams University Egypt MBBS Medicine
Date Title Institution Country 2005 - 2008 Master Degree in Clinical Oncology Ain Shams Univeristy Egypt
Date Title Institution name Country 2013 Speciality Certification of Medical Oncology Royal College of Physican United Kingdom 2010 Medical Oncology Certification European Society of Medical Oncology Italy
Year Citation 2018 Nassar, Z., Aref, A., Miladinovic, D., Mah, C., Raj, G., Hoy, A., & Butler, L. (2018). Peri-prostatic adipose tissue: the metabolic microenvironment of prostate cancer. BJU International, 121(Suppl. 3), 9-21.
DOI Scopus5 WoS4 Europe PMC1
2018 El-Ghazaly, H., Aref, A., & Bahie-eldin, N. (2018). Highlights from the 10th Breast, Gynaecological and Immunotherapy International Cancer Conference (BGICC), 18–19 January 2018, Cairo, Egypt. ecancermedicalscience, 12.
2018 Aref, A., Vincent, A. D., O'Callaghan, M., Martin, S., Sutherland, P., Hoy, A., . . . Wittert, G. (2018). The inverse relationship between prostate-specific antigen (PSA) and obesity. Endocrine-Related Cancer, 25(11), 933-941.
DOI Scopus4 WoS3 Europe PMC1
2017 Fayed, R., Hamza, D., Abdallah, H., Kelany, M., Tahseen, A., & Aref, A. (2017). Do we need regional guidelines for breast cancer management in the MENA region? MENA breast cancer guidelines project. ecancermedicalscience, 11, 783.
DOI Scopus1 Europe PMC1
2016 Aref, A. T., & Hamza, D. (2016). Screening of clinical practice in management of progression on trastuzumab in MBC. Journal of cancer prevention and current research, 5(1). 2014 Dawoud, E., Aref, A. T., Shorbagy, D., & Hamza, D. (2014). Panitumumab plus FOLFIRI vs. Bevacizumab plus FOLFIRI for First Line Treatment of Metastatic Colorectal Cancer with Wild-Type KRAS Tumors; a retrospective study. Austral-Asian journal of cancer, 13(1). 2014 Dawoud, E., Aref, A. T., Shorbagy, D., & Hamza, D. (2014). Panitumumab plus FOLFIRI vs. Bevacizumab plus FOLFIRI for First Line Treatment of Metastatic Colorectal Cancer with Wild-Type KRAS Tumors; a retrospective study. Austral-Asian journal of cancer, 13(1). 2014 Farid, I., Hamza, I., El-Abd, D., Mohyi, A., AbdulLatif, M., Aref, A., & Hamza, D. (2014). Transforming growth factor-β1 gene expression in hepatocellular carcinoma: A preliminary report. Arab Journal of Gastroenterology, 15(3-4), 142-147.
DOI Scopus1 WoS2
2013 Aref, A. T., & Hamza, D. (2013). Bevacizumab Beyond Progression in Metastatic NSCLC. Austral-Asian journal of cancer, 12.
Year Citation 2014 Aref, A. T. (2014). Ramucirumab and the Evolving Role of Targeted Therapy in Advanced Gastric Cancer. ESMO Young Oncologist Journal Club. 2014 Aref, A. T. (2014). New Options for Treatment of Metastatic Sarcoma Pose a Challenge in Selecting the Best One. ESMO Young Oncologist Journal Club. 2013 Aref, A. T. (2013). Continuation of Bevacizumab with Second-Line Chemotherapy after the Standard First-Line Bevacizumab-Containing Therapy in mCRC: What is the value of KRAS status?. ESMO Young Oncologist Journal Club.
Connect With Me